Dateline City:
WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.
Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C
WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the
companies have entered into a definitive agreement under which Merck
will acquire Idenix for $24.50 per share in cash. The transaction, which
values the purchase of Idenix at approximately $3.85 billion, has been
approved by the boards of directors of both companies.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Steve Cragle, 908-423-3461orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088orIdenixMedia/Investors:Teri Dahlman, 617-995-9807
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more